The oxazolidinone antibiotic linezolid has demonstrated potent antimicrobial activity against Gram-positive bacterial pathogens, including methicillin-resistant staphylococci. This article systematically reviews the published literature for reports of linezolid-resistant Staphylococcus (LRS) infections to identify epidemiological, microbiological and clinical features for these infections. Linezolid remains active against .98% of Staphylococcus, with resistance identified in 0.05% of Staphylococcus aureus and 1.4% of coagulase-negative Staphylococcus (CoNS). In all reported cases, patients were treated with linezolid prior to isolation of LRS, with mean times of 20.0+47.0 months for S. aureus and 11.0+8.0 days for CoNS. The most common mechanisms for linezolid resistance were mutation (G2576T) to the 23S rRNA (63.5% of LRSA and 60.2% of LRCoNS) or the presence of a transmissible cfr ribosomal methyltransferase (54.5% of LRSA and 15.9% of LRCoNS). The emergence of linezolid resistance in Staphylococcus poses significant challenges to the clinical treatment of infections caused by these organisms, and in particular CoNS.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) and methicillinresistant coagulase-negative Staphylococcus (MRCoNS) are major causes of both healthcare-and community-associated infections. 1 -3 Linezolid, with both oral and parenteral formulations, is one of the few therapeutic options shown to be effective against MRSA, including treatment of complicated skin and soft tissue infections (SSTIs), osteomyelitis, and pneumonia. 4 Little is known regarding the efficacy of linezolid for the treatment of serious infections caused by MRCoNS. In particular, linezolid is not approved for the treatment of patients with catheter-site or catheter-related bloodstream infections or infections where coagulase-negative Staphylococcus (CoNS) are commonly implicated.
Data from the USA and global surveillance studies report ,1% of S. aureus and 2% of CoNS 5 -9 are linezolid resistant. Nonetheless, multifocal outbreaks of linezolid-resistant Staphylococcus (LRS) have been reported, 10 -13 and both vertical and horizontal transmission of linezolid resistance determinants may occur. Very little data exist regarding treatment and clinical outcomes for LRS infections. A better understanding of the epidemiology and mechanisms of linezolid resistance are important to mandate judicious use of linezolid, both to preserve its clinical utility and prevent nosocomial transmission of LRS. Herein we systematically review the literature for all reported cases of LRS infection to document the current epidemiological, microbiological and clinical features of LRS infection.
Methods
A literature search was performed in PubMed and EMBASE through April 2012 using the National Library of Medicine's medical subject heading (MeSH) terms 'linezolid', 'staphylococcus', and 'resistance' for articles that reported linezolid-resistant Staphylococcus. The search was not restricted by language. The references cited in these articles were examined to identify additional reports. Linezolid resistance in Staphylococcus is defined by both the Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) as a linezolid MIC of ≥8 mg/L, and this breakpoint was used throughout interpretation of the literature.
Publications identified from the literature search were checked by title and abstract. If an article appeared relevant, the full text was reviewed. Articles included original articles, short communications, correspondences, letters or case reports that documented clinical isolates of linezolid-resistant Staphylococcus. Exclusion criteria were as follows: review articles, basic research on the mechanism of linezolid resistance, reports that described isolates with linezolid MICs ,8 mg/L and duplicate isolates reported in multiple studies.
Statistical 
Results

Incidence and epidemiology of linezolid resistance
Linezolid susceptibility among clinically significant isolates is monitored through two surveillance programmes, the global Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) and the USA Linezolid Experience and Accurate Determination of Resistance (LEADER). In these programmes, non-duplicate isolates from bacterial pneumonia and acute bacterial skin and skinstructure infections (ABSSSIs) are submitted by participating clinical laboratories and linezolid susceptibility is confirmed centrally using CLSI reference broth microdilution (BMD) MIC methods. Staphylococcus tested between 2002 and 2010 by both LEADER and ZAAPS were almost universally susceptible to linezolid (Table 1) . 5 
Clonal spread of LRS
Three reports of LRSA (13.6% of 22 studies) and 14 reports of LRCoNS (50% of 28 studies) documented clonal dissemination of LRS within or across healthcare settings (Table 2) . Two LRSA outbreaks were described in Spain, each involving a single hospital, and 15 or 12 patients, respectively. 13, 19 The third LRSA outbreak was reported from Japan, and involved seven patients in six different hospitals. 20 Both outbreaks in Spain were caused by LRSA harbouring the mobile cfr resistance gene, whereas the Japanese study did not test for cfr. Five linezolid-resistant S. epidermidis with identical PFGE types were recovered from patients at two geographically disparate institutions in the USA between 2006 and 2008. 7 In Greece, two clones of LRCoNS were identified among 26 patients in four hospitals. 21 Neither the US nor the Greek isolates harboured cfr. These publications did not distinguish LRCoNS colonization versus infection.
Mechanisms of linezolid resistance
Linezolid resistance occurs by mutations in the linezolid 23S rRNA binding site, the ribosomal proteins L3 and/or L4 of the peptide translocation centre of the ribosome or by acquisition of a plasmid-borne ribosomal methyltransferase gene, cfr.
22,23 All three mechanisms have been documented in LRSA and LRCoNS. 24 Sixty-three LRSA ( Figure 2 ) and 322 LRCoNS ( Figure 2 ) were investigated for mechanisms of linezolid resistance. While every molecular study evaluated the presence of the 23S rRNA G2576T mutation, a significant portion of the studies did not investigate cfr or L3/L4. More specifically, 52.4% of LRSA (n¼ 33/63 isolates tested) and 74.2% of LRCoNS 2002  502  ND  ND  0  ND  0  ND  2003  373  ND  ND  0  ND  0  ND  2004  419  2872  496  0  0  0  1  2005  465  3021  530  0  1  0  6  2006  657  2913  808  1  1  1  13  2007  1138  3318  1020  0  2  2  18  2008  1214  3156  856  0  3  3  15  2009  1184  3257  816  0  5  1  12  2010  3045  4540  676  0  1  3  8 ND, no data. Figure 2 ). G2576T was found among the majority of LRSA (63.5%, n¼ 63 isolates tested; Figure 2 ) and LRCoNS (60.2%, n¼322 isolates tested; Figure 2 ). cfr was detected in 18 (54.5%) of the LRSA tested ( Figure 2 ) and in only 38 (15.9%) of the LRCoNS tested (Figure 2 ). When bias imposed by testing of clonally related strains was removed, cfr was found in 10/25 (40%) unique LRSA and 10/54 (18.5%) unique LRCoNS. In all cases (21/21) with available information, LRSA was isolated following linezolid treatment, the mean duration of which was 20.0+47.0 months. All cases of CoNS infection (74/74 cases) with available information were also in patients previously treated with linezolid, with a mean duration of therapy of 11.0+8.0 days. The difference in exposure times to linezolid prior to isolation of LRSA and LRCoNS was significant (P,0.0001, Student's t-test). In vitro susceptibility data for antimicrobial agents in addition to linezolid were reported for 56.3% (234/416) of LRS strains reviewed (Table 3 ). All LRSA tested were resistant to oxacillin (n¼ 17), chloramphenicol (n¼15), and minocycline (n¼ 11) and susceptible to vancomycin (n¼ 33), daptomycin (n¼ 18), teicoplanin (n ¼33), tigecycline (n ¼15), amikacin (n¼ 12) and quinupristin/dalfopristin (n¼ 4). 25 All LRCoNS tested were susceptible to daptomycin (n¼176) and tigecycline (n¼ 80). 
Susceptibility testing and in vitro susceptibility data
Sites of infection
Discussion
In 2001, 1 year after linezolid was approved for clinical use, the first LRSA was reported in a US patient who had received a 1 month linezolid treatment for dialysis-associated peritonitis. 10 Since then, several cases of LRS have been reported in North and South America, Europe and Asia. While the incidence of linezolid resistance remains exceedingly low for S. aureus, more worrisome is the incidence of LRCoNS, which is roughly 28 times that of LRSA. One factor contributing to this increased incidence is the ability of CoNS to more readily develop resistance following linezolid exposure, although this has not been proven in vitro to our knowledge. The mean time of linezolid therapy reported prior to isolation of LRS was significantly shorter (11 days versus 20 months) for cases of LRCoNS. A second factor associated with selection for LRS is over-prescription of linezolid for staphylococcal bacteraemia, and in particular CoNS infections, as identified by the preponderance of LRCoNS isolated from the blood. However, this finding is likely biased by the fact that most clinical laboratories do not test antimicrobial susceptibility of CoNS unless isolated from a normally sterile site such as blood. Finally, significantly more LRCoNS were associated with outbreaks; 50% of the studies identified herein that investigated LRCoNS involved clonal LRCoNS, across one or more patients and facilities.
It is important to note that resistance rates among patients treated with linezolid for extended periods may be significantly elevated as compared with data reported in surveillance studies. For example, cystic fibrosis patients with respiratory tract infections caused by S. aureus have LRSA rates of up to 11%, directly related to the number and length of linezolid Review treatments. 19 Linezolid is the only antibiotic with good activity against MRSA available as an oral formulation, making it desirable for outpatient treatment. However, up to a quarter of patients prescribed the oral formulation of linezolid are nonadherent with therapy. 26 While all cases of LRS with available clinical data indicated prior exposure to linezolid, the formulation was only reported in three studies: two studies described oral 10, 19 and one parenteral dosing. 27 The relationship between compliance with linezolid therapy and linezolid resistance has not been formally evaluated, but may also be a factor driving linezolid resistance rates.
We identified a surprisingly high incidence of cfr among LRSA (40% of unique LRSA clones; Figure 2 ), a factor that strongly suggests horizontal gene transfer may be more common than previously appreciated. This finding raises significant concern about the possibility that isolates harbouring cfr may act as reservoirs for resistance. 28 Clonal spread of LRS with cfr has been documented in both institutional-level and multi-institutional outbreaks. 13, 20, 29, 30 Infection control practices targeted to halt the spread of MRSA should be effective at preventing the dissemination of LRSA; in contrast, CoNS are rarely considered true pathogens and LRCoNS may go unrecognized. These isolates then have the potential to transfer cfr to more pathogenic organisms, such as S. aureus. This concern is more than theoretical; Mendes and colleagues documented transmission of a mobile cfr onto two plasmids that were then acquired by Staphylococcus cohnii and Staphylococcus epidermidis isolated from the blood of two patients with sepsis. 28 Linezolid resistance may be under-reported based on technical hurdles in laboratory interpretation of both MIC and disc diffusion results. Compared with the standard CLSI BMD reference method, one study demonstrated 8/15 (53.3%) LRS were falsely reported susceptible by disc diffusion and 6/15 (40.0%) by Etest. 31 Errors in interpreting linezolid disc diffusion zones may be minimized by using endpoint reading recommendations published in the CLSI standards. 32 However, in our own unpublished observations, inter-user interpretation of the linezolid disc diffusion zones and MIC endpoints for the staphylococci 
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varied significantly, even among seasoned technologists. To address this concern, it is advisable that clinical laboratories confirm any LRS, preferably by a second method, prior to reporting, 32 something that was done in only 72% of the studies evaluated.
Treatment options for LRS are limited, but based on current in vitro susceptibility data, LRS remain universally susceptible to vancomycin, daptomycin and tigecycline. It is clear that the preservation of these antimicrobials for the treatment of infections cause by highly resistant organisms such as LRS is critical.
The results reported herein may suffer from publication bias and other biases inherent in single studies. Furthermore, the spread of clonally related isolates may overestimate the prevalence of LRS infections in healthcare settings.
Conclusions
Linezolid remains highly active against most staphylococci, and its value in treating serious infections caused by MRSA has been well documented. Clinicians should remain cognizant that linezolid resistance may arise following prolonged treatment with linezolid and of the possibility of LRS in patients that have not been previously treated with linezolid, given the high incidence of LRSA carrying cfr. Susceptibility testing for linezolid resistance should be considered prior to using linezolid for serious infections. Further, judicious use of linezolid, accurate identification of resistance and application of strict infection control measures are essential to the preservation of linezolid as a therapeutic agent. To date, LRS remain susceptible to vancomycin, daptomycin and tigecycline. Further studies are needed to investigate the clinical outcome of LRS infections in order to optimize treatment of these infections. Review
